KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Fulgent Genetics (FLGT) EBT (2016 - 2026)

Fulgent Genetics' EBT history spans 12 years, with the latest figure at -$26.0 million for Q1 2026.

  • On a quarterly basis, EBT fell 121.6% to -$26.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$22.5 million, a 49.24% increase, with the full-year FY2025 number at -$8.3 million, up 82.34% from a year prior.
  • EBT hit -$26.0 million in Q1 2026 for Fulgent Genetics, down from $32.5 million in the prior quarter.
  • Over the last five years, EBT for FLGT hit a ceiling of $202.0 million in Q1 2022 and a floor of -$33.5 million in Q4 2022.
  • Historically, EBT has averaged $4.5 million across 5 years, with a median of -$11.2 million in 2024.
  • Biggest five-year swings in EBT: plummeted 370.15% in 2024 and later surged 1219.4% in 2025.
  • Tracing FLGT's EBT over 5 years: stood at -$33.5 million in 2022, then skyrocketed by 106.78% to $2.3 million in 2023, then tumbled by 227.95% to -$2.9 million in 2024, then surged by 1219.4% to $32.5 million in 2025, then tumbled by 179.97% to -$26.0 million in 2026.
  • Business Quant data shows EBT for FLGT at -$26.0 million in Q1 2026, $32.5 million in Q4 2025, and -$7.5 million in Q3 2025.